Resolve Therapeutics Completed Phase 2 Trial Enrollment
The company finished recruiting 110 participants for its study on RSLV-132 in patients with Sjögren's disease.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical research is effectively improving treatment options for chronic autoimmune diseases?
Resolve Therapeutics has completed participant enrollment for a Phase 2 clinical trial evaluating the efficacy of RSLV-132. The study focuses on women suffering from moderate-to-severe symptoms of Sjögren's disease.
Why it matters
The trial seeks to determine if the experimental treatment can reduce systemic inflammation and improve cardinal symptoms by digesting extracellular RNA. This study marks a significant milestone in testing a potential new therapeutic approach for this autoimmune condition.
The study evaluates RSLV-132, an RNase-Fc fusion protein designed to digest extracellular RNA, which possesses a three-week serum half-life. Researchers are measuring changes from baseline in cardinal symptoms at Day 169.
The players
Resolve Therapeutics
The biotechnology company is the sponsor of the clinical trial for the novel drug candidate RSLV-132.
The details
The multicenter trial is testing RSLV-132 against a placebo to assess its ability to decrease activation of the innate immune system. Investigators are specifically monitoring how the drug interacts with RNA bound to autoantibodies to mitigate the patient disease burden.
Timeline
October 7, 2026: Resolve Therapeutics confirmed the completion of enrollment.
Day 169: The primary endpoint measurement for study participants.
Q2 2027: Expected timeline for the release of topline results.
The Tech Race
This trial represents a shift toward targeting extracellular RNA pathways to treat chronic autoimmune diseases. It moves beyond legacy symptom-management drugs by focusing on the underlying biological drivers of immune system over-activation.
Patients with moderate-to-severe Sjögren's disease are currently limited to existing therapies that focus on managing specific symptoms. This trial indicates that new, more targeted treatment options could become available to the public if the study results in Q2 2027 prove successful.
The takeaway
Clinical trials are essential for proving whether novel biotech treatments can safely improve patient quality of life. Participants and observers should look for the upcoming topline data release to understand the true potential of RSLV-132.
Further reading
For more background on ongoing research in this field, visit the Biotech section.
More information
View the full ClinicalTrials.gov study registration for more details on trial parameters.
Live Poll
Do you believe new pharmaceutical research is effectively improving treatment options for chronic autoimmune diseases?
